30-Oct-26

MOSt Market Roundup

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

motilal oswal
think wealth creation

Market Update

30-Oct-26

Nifty : 23,053.10 +116.35 (+0.51%) Sensex : 74,459.53 +308.49 (+0.42%)

- The equity benchmark Nifty gained nearly half a percent to close above the 23,000 mark, supported by strong buying in pharmaceutical and IT stocks amid encouraging quarterly earnings, renewed FII buying interest and attractive valuations. The Nifty advanced 116 points, or 0.5%, to settle at 23,053 while Nifty surged 2% during the month of October. Indian equity markets outperformed their global peers during the month, driven by robust corporate earnings.
- Pharma and IT stocks emerged as the major sectoral gainers, with both indices advancing around 2%. However, broader markets witnessed significant profit booking, with the Nifty 500 advance-decline ratio standing at 1:3, indicating widespread selling pressure in mid- and small-cap stocks.
- Technology stocks continued their strong momentum, with the Nifty IT index surging 2% today. The index has rallied over 17% in October, positioning it for its second-strongest monthly performance in more than two decades. Investors appeared to be shifting their preference from highly valued AI-focused stocks towards traditional IT services companies amid valuation concerns. Shares of Coforge, Infosys, Wipro, HCL Technologies and Tech Mahindra gained up to 4%.
- The Nifty Pharma index also advanced 2%, supported by impressive Q2 earnings announcements from Laurus Labs, Sun Pharma and Dr. Reddy's Laboratories. Laurus Labs surged 7% to close at Rs. 2405 per share.
- Among global markets, Asian and European equities declined by up to 3% as a sell-off in US technology stocks and concerns over rising investments in artificial intelligence weighed on investor sentiment. Markets in Taiwan, South Korea and Japan witnessed declines of up to 3%. Meanwhile, the Bank of Japan kept its benchmark interest rate unchanged at its latest monetary policy meeting.

Technical Outlook:

- Nifty index opened on a flattish note and witnessed support based buying near 22900 zones which helped the index stage a steady recovery. It reclaimed and comfortably sustained above the psychological 23K marks before closing near its upper band reflecting strength in the ongoing up move. It formed a bullish candle on the daily frame while the weekly frame also formed a bullish candle as bulls defended crucial support zones on larger timeframe and drove a recovery from the lower levels. Now it has to hold above 23000 zones for an up move towards 23150 then 23250 zones while support can be seen at 22900 then 22800 zones.
- S&P BSE Sensex index opened on a flattish note and after an initial dip towards 74000 zones, buying momentum continued and the index gradually inched higher towards 74700 in a slow and steady manner. Buying interest remained visible at lower levels helping the index maintain its upward momentum. It formed a bullish candle on the daily chart and is forming higher highs from the last couple of sessions. On the weekly scale, the index formed a strong bullish candle indicating improving market sentiment as multiple support levels remain intact and buying interest continues to emerge from lower levels. Now it has to hold above 74300 zones for a bounce towards 74800 then 75000 levels while on the downside support is seen at 74300 then 74000 zones.

Derivative Outlook:

- Nifty future closed positive with gains of 0.23% at 23101 levels. Positive setup seen in Aether Energy, Laurus Labs, Zydus Life, Coforge, Trent, Wipro, Infosys, LTM, Persistent, Sonacoms, Eternal and TCS while weakness seen in Suzlon, Amber, Inox Wind, Sagility, CAMS, UPL, VBL, Swiggy, Dixon, Crompton Greaves, LIC Housing and RVNL.
- On option front, maximum Call OI is at 23500 then 23100 strike while maximum Put OI is at 23000 then 22800 strike. Call writing is seen at 23100 then 23200 strike while Put writing is seen at 23000 then 22900 strike. Option data suggests a broader trading range in between 22700 to 23500 zones while an immediate range between 22900 to 23300 levels.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

30-Oct-26

Today's News

- **Sun Pharma's ILUMYA gets USFDA approval for psoriatic arthritis treatment –** Company said the US Food and Drug Administration (FDA) had approved its drug ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis, expanding its use beyond moderate-to-severe plaque psoriasis.
- **GAIL –** Company announce extend completion date of Kootanad Bengaluru- Mangaluru pipeline.
- **Escorts Kubota to raise Tractor p-rices in November –** Company will increase prices across its Kubota, Farmtrac and Powertrac tractor ranges in November due to rising input costs.
- **Hikal Ltd –** Company announce Swissmedic GMP compliance certification for its Bengaluru API facility, strengthening its presence in regulated global markets.
- **Max Healthcare –** Company announce Rs93cr for Noida Hospital expansion.

Global Market Update

- **Asian Market –** Asian stocks fell to remain on track for their worst month since March, as a US-tech selloff and concerns over the AI buildout weighed on investor sentiment. Taiwan, South Korea and Japan Index declined up to 3%. Bank Japan kept unchanged interest rate of today's policy meeting.
- **European Market –** European stocks slipped as renewed concerns over artificial intelligence spending rattled global markets, even as a fresh batch of earnings from AstraZeneca Plc, BP Plc and Sanofi SA lifted those shares. Both Germany and France Index declined 1% each.
- **Commodity –** Oil rose 1% to $116/bbl on signs the US may resume military strikes against Iran, risking fresh turbulence in the region that may hurt energy flows.

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

30-Oct-26

Pivot Table

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
NIFTY 50	23,053	22,905	22,812	22,933	23,025	23,146	23,238	23,118
ADANIENT	2,579	2,557	2,529	2,554	2,582	2,607	2,634	2,610
ADANIPORTS	1,850	1,814	1,787	1,819	1,845	1,877	1,903	1,872
APOLLOHOSP	8,448	8,176	8,085	8,267	8,357	8,539	8,629	8,448
ASIANPAINT	2,320	2,271	2,236	2,278	2,313	2,355	2,390	2,348
AXISBANK	1,217	1,209	1,199	1,208	1,218	1,227	1,236	1,228
BAJAJ-AUTO	10,350	10,309	10,175	10,263	10,396	10,484	10,617	10,530
BAJAJFINSV	1,668	1,658	1,647	1,657	1,669	1,679	1,691	1,680
BAJFINANCE	939	931	920	929	941	951	962	952
BEL	370	364	361	365	368	373	376	371
BHARTIARTL	1,974	1,958	1,945	1,959	1,972	1,986	1,999	1,985
BSE	3,510	3,466	3,441	3,476	3,500	3,535	3,560	3,525
CIPLA	1,379	1,357	1,348	1,363	1,373	1,388	1,397	1,382
COALINDIA	389	380	372	380	389	398	407	398
DRREDDY	1,352	1,345	1,335	1,343	1,354	1,362	1,372	1,364
EICHERMOT	7,220	7,198	7,109	7,164	7,254	7,309	7,399	7,343
ETERNAL	344	335	330	337	342	348	353	347
GRASIM	2,981	2,900	2,873	2,927	2,954	3,009	3,036	2,981
HCLTECH	1,428	1,410	1,388	1,408	1,430	1,450	1,472	1,452
HDFCBANK	693	681	675	684	690	699	704	696
HDFCLIFE	525	511	505	515	520	530	536	526
HINDALCO	885	876	868	876	884	893	901	893
HINDUNILVR	1,865	1,840	1,832	1,848	1,857	1,873	1,882	1,866
ICICIBANK	1,398	1,383	1,374	1,386	1,395	1,408	1,417	1,405
INDIGO	4,878	4,635	4,555	4,716	4,797	4,958	5,039	4,878

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
INFY	1,185	1,148	1,136	1,160	1,173	1,197	1,210	1,185
ITC	266	263	260	263	265	268	271	268
JIOFIN	205	205	203	204	205	206	208	207
JSWSTEEL	1,246	1,245	1,233	1,239	1,252	1,258	1,270	1,264
KOTAKBANK	462	457	455	458	461	464	466	463
LT	3,872	3,806	3,784	3,828	3,850	3,894	3,917	3,873
M&M	2,840	2,839	2,795	2,818	2,862	2,884	2,928	2,905
MARUTI	11,397	11,342	11,273	11,335	11,404	11,466	11,535	11,473
MAXHEALTH	860	849	831	845	864	879	898	883
NESTLEIND	1,167	1,165	1,152	1,160	1,172	1,180	1,192	1,185
NTPC	316	308	304	310	314	320	324	318
ONGC	225	224	223	224	226	227	229	228
POWERGRID	265	259	256	260	264	268	272	267
RELIANCE	1,165	1,153	1,142	1,153	1,164	1,176	1,186	1,175
SBILIFE	1,659	1,646	1,623	1,641	1,663	1,681	1,704	1,686
SBIN	962	960	952	957	964	969	977	972
SHRIRAMFIN	823	822	810	816	829	835	848	841
SUNPHARMA	1,778	1,766	1,711	1,744	1,800	1,833	1,888	1,855
TATACONSUM	1,026	1,002	993	1,009	1,019	1,036	1,046	1,029
TATASTEEL	168	167	166	167	168	168	169	169
TCS	2,503	2,494	2,475	2,489	2,508	2,522	2,542	2,528
TECHM	1,791	1,774	1,753	1,772	1,793	1,812	1,832	1,813
TITAN	4,437	4,391	4,343	4,390	4,438	4,485	4,533	4,486
TMPV	265	263	261	263	265	267	269	267
TRENT	3,017	2,980	2,939	2,978	3,019	3,058	3,099	3,060
ULTRACEMCO	11,045	11,004	10,918	10,981	11,068	11,131	11,218	11,154

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Siddhartha Khemka
Head - Retail Research

Chandan Taparia, CMT, CFTe, MFTA
Head - Derivatives & Technical Research

Disclosures:
The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:
a) received any compensation/other benefits from the subject company of this report
b) managed or co-managed public offering of securities from subject company of this research report,
c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

• MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
• Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
• Research Analyst may have served as director/officer/employee in the subject company.
• MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:
a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:
This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.
Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement
Analyst ownership of the stock No
A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:
This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.
MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .
In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.
Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Disclaimer:
This report is intended for distribution to Retail Investors.
The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be` suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.
Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.